% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Echchannaoui:300183,
      author       = {H. Echchannaoui$^*$ and K. J. Legscha$^*$ and M.
                      Theobald$^*$},
      title        = {{T}umor-{I}nfiltrating {L}ymphocytes, {CAR}-, and
                      {T}-{C}ell {R}eceptor-{M}odified {T} {C}ells in {S}olid
                      {C}ancer {O}ncology.},
      journal      = {Oncology research and treatment},
      volume       = {48},
      number       = {5},
      issn         = {2296-5270},
      address      = {Basel},
      publisher    = {Karger},
      reportid     = {DKFZ-2025-00660},
      pages        = {294-304},
      year         = {2025},
      note         = {2025;48(5):294-304},
      abstract     = {Adoptive cellular therapy (ACT) is a promising treatment
                      approach aiming at enhancing T-cell antitumor immune
                      response. ACT includes tumor-infiltrating lymphocytes,
                      chimeric antigen receptor (CAR) and T-cell receptor
                      gene-modified T cells. Despite a milestone achievement with
                      CAR-T cells in hematopoietic malignancies, ACT has shown
                      modest clinical responses in refractory solid cancers and
                      durable responses remain limited to a minor fraction of
                      patients.In this review, we highlight major advances,
                      limitations and current developments of T-cell therapies for
                      solid cancers. We discuss emerging promising strategies as
                      next-generation ACT, exploring local delivery routes to
                      maximize efficacy and improve safety, integrating predictive
                      biomarkers to optimize selection of patients who most likely
                      would benefit from ACT, using combination therapy to
                      overcome the immunosuppressive tumor microenvironment,
                      targeting multiple tumor antigen to avoid tumor antigen
                      escape, selection of the most potent T-cell product to
                      overcome T-cell dysfunction, and incorporating cutting-edge
                      new technologies, such as gene-editing to further improve
                      antitumor T-cell functions and reduce therapy-related
                      toxicity.Advances made in ACT trials have move the field of
                      immunotherapy for refractory solid cancers to a new stage,
                      by constantly incorporating new strategies to develop
                      next-generation therapies designed to enhance efficacy and
                      improve safety and to allow a broaden access to a large
                      numbers of patients.},
      subtyp        = {Review Article},
      keywords     = {Cellular immunotherapy (Other) / Chimeric antigen receptor
                      (Other) / Solid cancer (Other) / T-cell receptor (Other) /
                      Tumor infiltrating lymphocytes (Other)},
      cin          = {FM01},
      ddc          = {350},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39938499},
      doi          = {10.1159/000543998},
      url          = {https://inrepo02.dkfz.de/record/300183},
}